Carregant...

The Price Elasticity of Specialty Drug Use: Evidence from Cancer Patients in Medicare Part D

Specialty drugs can bring substantial benefits to patients with debilitating conditions, such as cancer, but their costs are very high. Insurers/payers have increased patient cost-sharing for specialty drugs to manage specialty drug spending. We utilized Medicare Part D plan formulary data to create...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Forum Health Econ Policy
Autors principals: Jung, Jeah Kyoungrae, Feldman, Roger, McBean, A. Marshall
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5877476/
https://ncbi.nlm.nih.gov/pubmed/29610565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!